Using Circadian Heart Rate to assess the Impact of Chronic Stress and Mental Health

March 2016
We believe individuals, families and carers affected by mental health can live full, happy & healthy lives.

Redefining mental health by making the intangible, tangible.
Forward looking statements

The purpose of the presentation is to provide an update of the business of Medibio Limited (ASX:MEB). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfilment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Medibio Limited’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Because actual results could differ materially to assumptions made and Medibio Limited’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events. This presentation should not be relied on as a recommendation or forecast by Medibio Limited. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.
Company Summary

• Medibio’s digital mental health platform will transform the assessment and management of mental health

• Defensible IP/technology based on 20 years of research into the relationship between the autonomic nervous system and mental health

• Support of notable research partners - Johns Hopkins University, Mayo Clinic, Emory University, Ottawa University, BMRI

• FDA submission this year and existing reimbursement codes to pave the way for clinical and corporate acceptance

• Multiple commercialisation routes – Clinical, Pharma, B2B and B2C represent multi-billion dollar market opportunities

• B2B product on market now and in use with key strategic partners

“It is critical to realise that we cannot succeed if we use DSM categories as the gold standard. We need a quantitative method for diagnosing depression.”

(U.S. National Institute of Mental Health - 2013)
“The Single Greatest Illness that Affects Mankind” *

- Neuropsychiatric disorders are the leading cause of disability in the U.S.

- WHO estimates the global cost of mental illness as $2.5T in 2010 (est. $6T in 2030)

References
- NIMH article

* World Mental Health Day 2015
Professor Stephen Lawrie, Head of Psychiatry at Edinburgh

Data courtesy of WHO
A Global Crisis of Access & Management

350 Million People With Depression

1 Million Suicides Every Year

27% of adults in Europe

1.5 psychiatrists per 100,000 people in China

26% of adults in USA

7.8 psychiatrists per 100,000 people in USA

0.3 psychiatrists per 100,000 people in India
Snowball Effect of Depression

Patients diagnosed with MDD are far more likely to develop serious co-morbidities.

Direct cost to treat Major Depressive Disorder (MDD) care in US.

- $6,425 (per year)
- 10x
- Increased risk of overall functional impairment; poor sleep quality, decreased activity, poor self-care and increased substance abuse.
- Additional direct cost to treat diabetics with depression.
- 3x
- Increase in mortality in CVD patients with depression.

+$3,120 (per year)
The Need for Objectivity

“The economic costs of mental illness will be more than cancer, diabetes & respiratory ailments put together.”

Thomas Insel, MD – Former Director National Institute of Mental Health

Current Pain Points

• No objective test for mental illness.
• The diagnostic “gold standard” is a clinical/expert opinion.
• Diagnostic agreement between clinicians can vary considerably – concordance rates near 70%.
• Current assessments are subjective which can lead to inadequate or incorrect diagnosis.
• Misdiagnosis of depression (and other mental illness) places a huge cost burden on the healthcare system and the workplace.

Medibio’s Solution

• Quantitative, objective test.
• Diagnosis based on patient’s biometric data (circadian heart rate waveform).
• Repeatable, reliable test with classification accuracy of >80%.
• Provides objective indication of treatment efficacy along with medication compliance and adherence.
• Savings to the health system and better patient outcomes.
Medibio’s Digital Mental Health Platform will transform the assessment and management of mental health by:

- Enabling access to care
- Providing objective, quantifiable diagnosis
- Confirming the effectiveness of therapies
- Driving optimal disease management
The Mind-Heart Link

• The psychosomatic link between the heart and emotion has been recognized since antiquity and is embedded in language (‘made my heart skip a beat... heart broken... cold hearted’)

• 5000 years ago, Ayurvedic physicians diagnosed mental illness by feeling a person’s pulse!

• The heart is not merely a pump. It has a neuronal circuitry of around 40000 neurones, secretes hormones [A&B natriuretic, norepinephrine & dopamine (ICA cells), oxytocin], has endocrine receptors and has dense interconnections with different parts of the brain.

• The autonomic nervous system (ANS) plays a key role in circadian sleep-wake regulation which includes heart rate.

• All serious mental illness (SMI) are associated with ANS and wider neuroendocrine dysregulation (especially affective disorders) and abnormalities in circadian regulation.
Insights Based on 20 years of Clinical Experience

- Research initiated 20 years ago at University of Western Australia to test the theory that mental state linked ANS disturbance could be observed via the cardiovascular system.

- Mental state-linked ANS disturbance is observed via the cardiovascular system during sleep when external influences are absent.

- Morphologic analysis of circadian heart rate waveforms (CHR) gives objective indications of ‘core’ physiological differences between different forms of mental illness such as anxiety, depression, and stress.

- Serial monitoring of patients under psychiatric treatment showed that effective intervention is associated with normalisation of CHR, providing a tool for determining treatment effectiveness.
Objective Assessment of Therapy Effectiveness

Case Study 1
• Depressed individual upon initial diagnosis
• Treated for 18 days with:
  • Olanzapine – 10mg (night)
  • Mirtazapine – 60mg (night)

Case Study 2
• Individual diagnosed with Generalized Anxiety Disorder (GAD)
• Re-evaluated 10 days following effective treatment
## Significant Validation Supporting Technology

<table>
<thead>
<tr>
<th>CLASSIFICATION ACCURACY</th>
<th>STUDY OUTLINE</th>
<th>REFERENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>98%</td>
<td>32 controls (normals) and 28 with either an affective disorder or a psychotic disorder</td>
<td>International Congress on Schizophrenia – 2003</td>
</tr>
<tr>
<td>78%</td>
<td>50 across the mental health continuum</td>
<td>Psychiatric Quarterly, Vol. 73, No. 3, Fall 2002 (2002)</td>
</tr>
<tr>
<td>80%</td>
<td>98 patients, mixed psychopathology and normals</td>
<td>Diligence by UNSW and Newcastle University independent researchers</td>
</tr>
<tr>
<td>82%</td>
<td>200 patients, 30 normals, 30 depression, 30 GAD, 110 other mixed psychopathologies</td>
<td>Australian &amp; New Zealand Journal of Psychiatry 1998; 32; 187-198</td>
</tr>
</tbody>
</table>
Defensible Position Based on Decades of Research

Comprehensive suite of patents around CHR & technology:

- Medical diagnostics including assessment of treatment efficacy
- Stress assessment

Patent suite for medical diagnostics includes:

- Method for Diagnosing Psychiatric Disorders
- Method and System for Monitoring Stress Conditions covering the use of CHR for stress assessment
- Method and System for using CHR to Diagnose Psychiatric Disorders

Proprietary data set required is the natural protection:

- 10,000+ 12 hour ECG files with a corresponding psychiatric diagnosis
- This data set would take 5 years and cost $20 million to replicate
Opportunities in Multiple Broad Markets

**REGULATED**

**MEDICAL**
US $30Bn Industry
- Primary Care Physicians
- Psychiatrists
- Psychologists
- Therapists
- Counsellors
- Cardiologists

**PHARMA**
US $76Bn Industry
- Global Pharma companies
- Clinical trial organizations
- Companion diagnostics

**B2B**
US $19Bn Industry
- High Risk Occupations
  - Defence
  - Police/Fire/Emergency
- Govt / Corporate Wellness
- SME Health and Wellbeing
- Elite Sports

**B2C**
US $26Bn Industry
- Direct to Consumer
- Insurance Companies
- Wellness Providers
- Digital Health Companies

**UNREGULATED**
# Robust Roadmap into Multi-billion $ Verticals

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stress</td>
<td>Stress</td>
<td>Workplace</td>
<td>Personalized</td>
<td>Benchmarking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monitoring</td>
<td>Monitoring</td>
<td>Analytics</td>
<td>Interventions</td>
<td>&amp; Management</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stress</td>
<td>Stress</td>
<td>Biofeedback</td>
<td>In-app</td>
<td>Tele-consulting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monitoring</td>
<td>Monitoring</td>
<td></td>
<td>Coaching</td>
<td>Services</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-clinical</td>
<td>Pre-clinical</td>
<td>ID of non-</td>
<td>Companion</td>
<td>Outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening</td>
<td>Screening</td>
<td>responders</td>
<td>Diagnostic</td>
<td>Confirmation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medical</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic</td>
<td>Diagnostic</td>
<td>Therapy</td>
<td>Adherence</td>
<td>Patient</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aid</td>
<td>Aid</td>
<td>Effectiveness</td>
<td>Monitoring</td>
<td>Management</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Significantly Improving the Patient Journey

Typical MDD Patient Journey → Years to Proper Treatment

<table>
<thead>
<tr>
<th>Developing Condition</th>
<th>Undiagnosed Condition</th>
<th>Diagnosis</th>
<th>Treatment Titration</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variable</td>
<td>3-6 months</td>
<td>3-6 months over multiple doctor visits</td>
<td>3-6 months over multiple doctor visits</td>
<td>Episodic doctor visit every 3-6 months</td>
</tr>
</tbody>
</table>

Digital Mental Health → Continuous & Real-time

<table>
<thead>
<tr>
<th>Monitoring &amp; Diagnosis</th>
<th>Treatment Titration</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous feedback &amp; diagnosis</td>
<td>Remote, daily feedback on drug effectiveness</td>
<td>Continuous feedback &amp; management / data-based doctor visits</td>
</tr>
</tbody>
</table>

$3,000/yr

Difference in annual direct costs between managed and unmanaged depression.
Clinical Work Flow

1. Clinician orders test
2. Wearable device (holter) collects CHR data from patient
3. Medibio App connects with device & data transmitted to HIPAA compliant Cloud
4. Data processed by machine learning algorithms in the Cloud
5. Clinician has secure access to results – anywhere / anytime
Clinical Market Opportunity

- PCP's in the US are becoming the primary psychiatric care provider with in excess of 50% of all psychiatric diagnosis

- Of the 21 million annual PCP visits in the US which are mental health related:
  - 40% receive only psychiatric medication
  - 30% receive medication and are given some therapy
  - 30% are referred to a psychiatrist/psychologist

- Will be marketed as a diagnostic aid with the early adopter PCPs

- Model based on the current structure for ambulatory ECG monitoring

<table>
<thead>
<tr>
<th>CPT CODE</th>
<th>MEDICARE</th>
<th>PRIVATE</th>
<th>INSURANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>93225</td>
<td>Recording (Provider)</td>
<td>$26.87</td>
<td>$40</td>
</tr>
<tr>
<td>93226</td>
<td>Analysis with Report (Medibio)</td>
<td>$37.91</td>
<td>$57</td>
</tr>
<tr>
<td>93227</td>
<td>Physician review and Interpretation (Provider)</td>
<td>$26.87</td>
<td>$40</td>
</tr>
</tbody>
</table>

- PCP Initial diagnostic market –
  21 million annual PCP visits @ $45
  $1 billion annually (TAM)

- Ongoing monitoring – 16 million with depression in US quarterly @
  $22.50 $1.6 billion annually (TAM)

- 5% penetration of the US market for depression diagnosis would generate revenue of $175 million annually

- Cloud based analysis and reporting = minimal costs per report = very high margins
Corporate Wellness is a Large & Growing Market

Value Proposition
• 43% of the adults in the US suffer adverse health effects from stress
• Stress is estimated to cost US employees $300 billion annually
• Over half of the 550 million working days lost annually in the U.S.
• Stress is estimated to cause 30% of employee turnover

US Market Size
• 54 million employees in the US (+1,000 staff firms)
• 90% of corporates have an existing wellness program
• Annual wellness spend $100-$500 per employee, US$4BN revenue potential

Go to market strategy
• Partner with existing participants in the Corporate Wellness market
• Medibio will provide data analytics and reporting – our core competency

1. www.stress.org/workplace-stress
3. US Census

Starbucks spends more on employee benefits than on coffee.

Of chief financial officers cited healthcare costs as their main financial concern.

SOLUTION
$1 spent on health promotion & disease prevention = $5 decrease in overall medical costs.
Aggressive Revenue Growth Potential

- Service delivery model through Wellness Channel partners
- Medibio as a catalyst for changing business models (e.g. Digital)
  - Enable innovation
  - Increased use of Services (Existing/New)
  - Broader coverage of Services (Existing/New)
- Subscription pricing model
  - Stress Monitoring
  - User Analytics
  - Client Analytics
  - Provider Analytics
- 5% penetration of the US market would generate $247 million annual revenue
B2C Market Opportunity

All Apps related to stress/mental health are:
• based on reducing tension via breathing, yoga, and relaxing sounds
• mental health Apps are based on a digitised version of the DSM
• **none offer objective stress assessment based on extended research**

**Medibio’s App**
• An health sector endorsed, objective stress assessment application and management tool
• Integration testing with popular wearable devices underway as a precursor to commercial launch decision

**Business Model**
• Initial download cost gives you a month of complete usage including the stress management interventions
• Subscription based model for a 12 month
• Nearest competitor is “Stress Doctor” which has generated 60+ million iOS downloads
# Key Company Milestones

<table>
<thead>
<tr>
<th>TIMING</th>
<th>MILESTONE</th>
<th>STATUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 2016</td>
<td>Commence commercial stress pilots (2 separate customers)</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>FDA Feedback on Pre-submission package</td>
<td></td>
</tr>
<tr>
<td>Q2 2016</td>
<td>Completion of wearable testing program with NTICA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Announcement of Foundation Partner for Australian Corporate Stress Rollout</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Start Independent Validation Study Corporate Stress product</td>
<td></td>
</tr>
<tr>
<td>Q3 2016</td>
<td>Completion of commercial stress pilots (2 separate pilots)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Binding Commercial Agreement with Medtronic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Decision on launch of Consumer Stress App</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Announcement of second Regional Foundation Partner</td>
<td></td>
</tr>
<tr>
<td>Q4 2016</td>
<td>Completion of John Hopkins University Validation Study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lodgement of FDA Application (Depression Diagnostic)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Results from University of Ottawa Study</td>
<td></td>
</tr>
</tbody>
</table>